Cargando…
HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy
Introduction: The incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to predict response to treatment and increase overall sur...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958932/ https://www.ncbi.nlm.nih.gov/pubmed/36837562 http://dx.doi.org/10.3390/medicina59020361 |
_version_ | 1784895147466555392 |
---|---|
author | Zděblová Čermáková, Zuzana Hurník, Pavel Konvalinka, David Štembírek, Jan Paračková, Tereza Resová, Kamila Cvek, Jakub Blažek, Tomáš Knybel, Lukáš Formánek, Martin Gachechiladze, Mariam Joerger, Markus Soltermann, Alex Škarda, Jozef Motyka, Oldřich Janoutová, Jana |
author_facet | Zděblová Čermáková, Zuzana Hurník, Pavel Konvalinka, David Štembírek, Jan Paračková, Tereza Resová, Kamila Cvek, Jakub Blažek, Tomáš Knybel, Lukáš Formánek, Martin Gachechiladze, Mariam Joerger, Markus Soltermann, Alex Škarda, Jozef Motyka, Oldřich Janoutová, Jana |
author_sort | Zděblová Čermáková, Zuzana |
collection | PubMed |
description | Introduction: The incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to predict response to treatment and increase overall survival is underway. Objective: This study aimed to analyze the presence of 32 HPV genotypes in tumor samples of 34 patients and the effect of HPV status and RAD51 on overall survival. Method: Tumor samples of 34 patients with locally advanced oropharyngeal or oral cavity cancer treated with accelerated radiotherapy in monotherapy were analyzed using reverse hybridization and immunohistochemistry for the presence of HPV and RAD51. Its effect on overall survival was examined. Results: Only two types of HPV were identified—HPV 16 (dominant) and HPV 66 (two samples). The HPV positivity was associated with a borderline insignificant improvement in 2-year (p = 0.083), 5-year (p = 0.159), and overall survival (p = 0.083). Similarly, the RAD51 overexpression was associated with borderline insignificant improvement in 2-year (p = 0.083) and 5-year (p = 0.159) survival. Conclusion: We found no statistically significant differences but detected trends toward improvement in the survival of HPV-positive and RAD51 overexpressing patients unfit for surgical treatment or chemotherapy treated with hyperfractionated radiotherapy. The trends, however, indicate that in a larger group of patients, the effects of these two parameters would likely be statistically significant. |
format | Online Article Text |
id | pubmed-9958932 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99589322023-02-26 HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy Zděblová Čermáková, Zuzana Hurník, Pavel Konvalinka, David Štembírek, Jan Paračková, Tereza Resová, Kamila Cvek, Jakub Blažek, Tomáš Knybel, Lukáš Formánek, Martin Gachechiladze, Mariam Joerger, Markus Soltermann, Alex Škarda, Jozef Motyka, Oldřich Janoutová, Jana Medicina (Kaunas) Article Introduction: The incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to predict response to treatment and increase overall survival is underway. Objective: This study aimed to analyze the presence of 32 HPV genotypes in tumor samples of 34 patients and the effect of HPV status and RAD51 on overall survival. Method: Tumor samples of 34 patients with locally advanced oropharyngeal or oral cavity cancer treated with accelerated radiotherapy in monotherapy were analyzed using reverse hybridization and immunohistochemistry for the presence of HPV and RAD51. Its effect on overall survival was examined. Results: Only two types of HPV were identified—HPV 16 (dominant) and HPV 66 (two samples). The HPV positivity was associated with a borderline insignificant improvement in 2-year (p = 0.083), 5-year (p = 0.159), and overall survival (p = 0.083). Similarly, the RAD51 overexpression was associated with borderline insignificant improvement in 2-year (p = 0.083) and 5-year (p = 0.159) survival. Conclusion: We found no statistically significant differences but detected trends toward improvement in the survival of HPV-positive and RAD51 overexpressing patients unfit for surgical treatment or chemotherapy treated with hyperfractionated radiotherapy. The trends, however, indicate that in a larger group of patients, the effects of these two parameters would likely be statistically significant. MDPI 2023-02-14 /pmc/articles/PMC9958932/ /pubmed/36837562 http://dx.doi.org/10.3390/medicina59020361 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zděblová Čermáková, Zuzana Hurník, Pavel Konvalinka, David Štembírek, Jan Paračková, Tereza Resová, Kamila Cvek, Jakub Blažek, Tomáš Knybel, Lukáš Formánek, Martin Gachechiladze, Mariam Joerger, Markus Soltermann, Alex Škarda, Jozef Motyka, Oldřich Janoutová, Jana HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy |
title | HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy |
title_full | HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy |
title_fullStr | HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy |
title_full_unstemmed | HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy |
title_short | HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy |
title_sort | hpv and rad51 as prognostic factors for survival in inoperable oral and oropharyngeal cancer in patients unfit for chemotherapy treated with hyperfractionated radiotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958932/ https://www.ncbi.nlm.nih.gov/pubmed/36837562 http://dx.doi.org/10.3390/medicina59020361 |
work_keys_str_mv | AT zdeblovacermakovazuzana hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy AT hurnikpavel hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy AT konvalinkadavid hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy AT stembirekjan hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy AT parackovatereza hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy AT resovakamila hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy AT cvekjakub hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy AT blazektomas hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy AT knybellukas hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy AT formanekmartin hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy AT gachechiladzemariam hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy AT joergermarkus hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy AT soltermannalex hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy AT skardajozef hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy AT motykaoldrich hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy AT janoutovajana hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy |